Award details

More Medicines for Tuberculosis

Reference	BBS/E/J/000CA436
Principal Investigator / Supervisor	Professor Anthony Maxwell
Co-Investigators / Co-Supervisors
Institution	John Innes Centre
Department	John Innes Centre Department
Funding type	Research
Value (£)	203,422
Status	Current
Type	Institute Project
Start date	01/02/2011
End date	31/07/2016
Duration	65 months

Abstract

The More Medicines for Tuberculosis (MM4TB - EU FP7) consortium has evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), which delivered a candidate drug for clinical development. Building on these foundations, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. The role of JIC (AM lab) will be to develop M. tuberculosis gyrase as a target and establishing the mechanism of action of novel compounds that target this enzyme. This will involve biochemistry and structural methods (X-ray crystallography), carried out in collaboration with the Lawson laboratory. Medicinal chemistry, carried out in other labs in the consortium, will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.

Summary

unavailable

Committee	Not funded via Committee
Research Topics	Microbiology, Pharmaceuticals, Structural Biology
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search